MedKoo product information:

 Porfiromycin

porfiromycin is an N-methyl derivative of the antineoplastic antibiotic mitomycin C isolated from the bacterium Streptomyces ardus and other Streptomyces bacterial species. Bioreduced porfiromycin generates oxygen radicals and alkylates DNA, producing interstrand cross-links and single-strand breaks, thereby inhibiting DNA synthesis. Porfiromycin is preferentially toxic to hypoxic cells. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

  1: McKeown SR, Cowen RL, Williams KJ. Bioreductive drugs: from concept to clinic. Clin Oncol (R Coll Radiol). 2007 Aug;19(6):427-42. Epub 2007 May 4. Review. PubMed PMID: 17482438.

2: Na Y. Solvolysis study of cycliciminomitomycins. Chem Pharm Bull (Tokyo). 2007 Mar;55(3):482-7. PubMed PMID: 17329899.

3: Rewari AN, Haffty BG, Wilson LD, Son YH, Joe JK, Ross DA, Papac RJ, Sasaki CT, Fischer JJ. Postoperative concurrent chemoradiotherapy with mitomycin in advanced squamous cell carcinoma of the head and neck: results from three prospective randomized trials. Cancer J. 2006 Mar-Apr;12(2):123-9. PubMed PMID: 16630403.

4: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2005 Jun;27(5):331-72. PubMed PMID: 16082422.

5: Haffty BG, Wilson LD, Son YH, Cho EI, Papac RJ, Fischer DB, Rockwell S, Sartorelli AC, Ross DA, Sasaki CT, Fischer JJ. Concurrent chemo-radiotherapy with mitomycin C compared with porfiromycin in squamous cell cancer of the head and neck: final results of a randomized clinical trial. Int J Radiat Oncol Biol Phys. 2005 Jan 1;61(1):119-28. PubMed PMID: 15629602.

6: Eisbruch A, Normolle DP. Testing new chemoradiation regimens for head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2005 Jan 1;61(1):5-6. PubMed PMID: 15629586.

7: Lee SH, Kohn H. Cyclic disulfide C8 iminoporfiromycin: nucleophilic activation of a porfiromycin. J Am Chem Soc. 2004 Apr 7;126(13):4281-92. PubMed PMID: 15053618.

8: Na Y, Wang S, Kohn H. 7-N-(mercaptoalkyl)mitomycins: implications of cyclization for drug function. J Am Chem Soc. 2002 May 1;124(17):4666-77. PubMed PMID: 11971715.

9: Bolzán AD, Bianchi MS. Genotoxicity of streptonigrin: a review. Mutat Res. 2001 Mar;488(1):25-37. Review. PubMed PMID: 11223403.

10: Denny WA, Wilson WR. Tirapazamine: a bioreductive anticancer drug that exploits tumour hypoxia. Expert Opin Investig Drugs. 2000 Dec;9(12):2889-901. Review. PubMed PMID: 11093359.

11: Begleiter A. Clinical applications of quinone-containing alkylating agents. Front Biosci. 2000 Nov 1;5:E153-71. Review. PubMed PMID: 11056078.

12: Lang W, Mao J, Doyle TW, Almassian B. Isolation and identification of urinary metabolites of porfiromycin in dogs and humans. Drug Metab Dispos. 2000 Aug;28(8):899-904. PubMed PMID: 10901698.

13: Lang W, Mao J, Wang Q, Niu C, Doyle TW, Almassian B. Isolation and identification of metabolites of porfiromycin formed in the presence of a rat liver preparation. J Pharm Sci. 2000 Feb;89(2):191-8. PubMed PMID: 10688748.

14: Lee AE, Wilson WR. Hypoxia-dependent retinal toxicity of bioreductive anticancer prodrugs in mice. Toxicol Appl Pharmacol. 2000 Feb 15;163(1):50-9. PubMed PMID: 10662604.

15: Belcourt MF, Penketh PG, Hodnick WF, Johnson DA, Sherman DH, Rockwell S, Sartorelli AC. Mitomycin resistance in mammalian cells expressing the bacterial mitomycin C resistance protein MCRA. Proc Natl Acad Sci U S A. 1999 Aug 31;96(18):10489-94. PubMed PMID: 10468636; PubMed Central PMCID: PMC17916.

16: Prieto-Alamo MJ, Laval F. Overexpression of the human HAP1 protein sensitizes cells to the lethal effect of bioreductive drugs. Carcinogenesis. 1999 Mar;20(3):415-9. PubMed PMID: 10190555.

17: Belcourt MF, Hodnick WF, Rockwell S, Sartorelli AC. Exploring the mechanistic aspects of mitomycin antibiotic bioactivation in Chinese hamster ovary cells overexpressing NADPH:cytochrome C (P-450) reductase and DT-diaphorase. Adv Enzyme Regul. 1998;38:111-33. PubMed PMID: 9762350.

18: Belcourt MF, Hodnick WF, Rockwell S, Sartorelli AC. The intracellular location of NADH:cytochrome b5 reductase modulates the cytotoxicity of the mitomycins to Chinese hamster ovary cells. J Biol Chem. 1998 Apr 10;273(15):8875-81. PubMed PMID: 9535868.

19: Joseph G, Biederbick W, Woschée U, Theisohn M, Klaus W. Sensitive and convenient high-performance liquid chromatographic method for the determination of mitomycin C in human plasma. J Chromatogr B Biomed Sci Appl. 1997 Sep 26;698(1-2):261-7. PubMed PMID: 9367216.

20: Paroni R, Arcelloni C, De Vecchi E, Fermo I, Mauri D, Colombo R. Plasma mitomycin C concentrations determined by HPLC coupled to solid-phase extraction. Clin Chem. 1997 Apr;43(4):615-8. PubMed PMID: 9105262.

21: Haffty BG, Son YH, Wilson LD, Papac R, Fischer D, Rockwell S, Sartorelli AC, Ross D, Sasaki CT, Fischer JJ. Bioreductive alkylating agent porfiromycin in combination with radiation therapy for the management of squamous cell carcinoma of the head and neck. Radiat Oncol Investig. 1997;5(5):235-45. PubMed PMID: 9372546.

22: Wakusawa S, Nakamura S, Miyamoto K. Establishment by adriamycin exposure of multidrug-resistant rat ascites hepatoma AH130 cells showing low DT-diaphorase activity and high cross resistance to mitomycins. Jpn J Cancer Res. 1997 Jan;88(1):88-96. PubMed PMID: 9045901.

23: Huh N, Rege AA, Yoo B, Kogan TP, Kohn H. Design, synthesis, and evaluation of mitomycin-tethered phosphorothioate oligodeoxynucleotides. Bioconjug Chem. 1996 Nov-Dec;7(6):659-69. PubMed PMID: 8950485.

24: Belcourt MF, Hodnick WF, Rockwell S, Sartorelli AC. Bioactivation of mitomycin antibiotics by aerobic and hypoxic Chinese hamster ovary cells overexpressing DT-diaphorase. Biochem Pharmacol. 1996 Jun 28;51(12):1669-78. PubMed PMID: 8687482.

25: Rockwell S, Kelley M. Interactions of BMS-181174 and radiation: studies with EMT6 cells in vitro and in solid tumors. Radiother Oncol. 1996 Apr;39(1):65-71. PubMed PMID: 8735495.

26: Belcourt MF, Hodnick WF, Rockwell S, Sartorelli AC. Differential toxicity of mitomycin C and porfiromycin to aerobic and hypoxic Chinese hamster ovary cells overexpressing human NADPH:cytochrome c (P-450) reductase. Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):456-60. PubMed PMID: 8552660; PubMed Central PMCID: PMC40257.

27: Brown JM, Siim BG. Hypoxia-Specific Cytotoxins in Cancer Therapy. Semin Radiat Oncol. 1996 Jan;6(1):22-36. PubMed PMID: 10717159.

28: Kumar GS, He QY, Behr-Ventura D, Tomasz M. Binding of 2,7-diaminomitosene to DNA: model for the precovalent recognition of DNA by activated mitomycin C. Biochemistry. 1995 Feb 28;34(8):2662-71. PubMed PMID: 7873548.

29: Grandis JR, Chang MJ, Yu WD, Johnson CS. Antitumor activity of interleukin-1 alpha and cisplatin in a murine model system. Arch Otolaryngol Head Neck Surg. 1995 Feb;121(2):197-200. PubMed PMID: 7840928.

30: Caron RM, Hamilton JW. Preferential effects of the chemotherapeutic DNA crosslinking agent mitomycin C on inducible gene expression in vivo. Environ Mol Mutagen. 1995;25(1):4-11. PubMed PMID: 7875125.

31: Sartorelli AC, Belcourt MF, Hodnick WF, Keyes SR, Pritsos CA, Rockwell S. Preferential kill of hypoxic EMT6 mammary tumor cells by the bioreductive alkylating agent porfiromycin. Adv Enzyme Regul. 1995;35:117-30. PubMed PMID: 7572339.

32: Adams GE, Stratford IJ. Bioreductive drugs for cancer therapy: the search for tumor specificity. Int J Radiat Oncol Biol Phys. 1994 May 15;29(2):231-8. PubMed PMID: 8195012.

33: Rockwell S, Hughes CS. Effects of mitomycin C and porfiromycin on exponentially growing and plateau phase cultures. Cell Prolif. 1994 Mar;27(3):153-63. PubMed PMID: 10465006.

34: Siegel D, Beall H, Kasai M, Arai H, Gibson NW, Ross D. pH-dependent inactivation of DT-diaphorase by mitomycin C and porfiromycin. Mol Pharmacol. 1993 Dec;44(6):1128-34. PubMed PMID: 8264549.

35: Yu F, Pan SS. Effect of pH on DNA alkylation by enzyme-activated mitomycin C and porfiromycin. Mol Pharmacol. 1993 Jun;43(6):863-9. PubMed PMID: 8391116.

36: Rauth AM, Marshall RS, Kuehl BL. Cellular approaches to bioreductive drug mechanisms. Cancer Metastasis Rev. 1993 Jun;12(2):153-64. Review. PubMed PMID: 8375018.

37: Rockwell S, Hughes CS, Keyes SR, Sartorelli AC, Kennedy KA. Porfiromycin as an adjunct to radiotherapy in young and old mice. Exp Gerontol. 1993 May-Jun;28(3):281-93. PubMed PMID: 8344398.

38: Cummings J, Chirrey L, Willmott N, Halbert GW, Smyth JF. Determination of mitomycin C, 2,7-diaminomitosene, 1,2-cis- and 1,2-trans-1-hydroxy-2,7-diaminomitosene in tumour tissue by high-performance liquid chromatography. J Chromatogr. 1993 Jan 29;612(1):105-13. PubMed PMID: 8454690.

39: Sartorelli AC, Tomasz M, Rockwell S. Studies on the mechanism of the cytotoxic action of the mitomycin antibiotics in hypoxic and oxygenated EMT6 cells. Adv Enzyme Regul. 1993;33:3-17. PubMed PMID: 8356915.

40: Robertson N, Stratford IJ, Houlbrook S, Carmichael J, Adams GE. The sensitivity of human tumour cells to quinone bioreductive drugs: what role for DT-diaphorase? Biochem Pharmacol. 1992 Aug 4;44(3):409-12. PubMed PMID: 1510692.

41: Durand RE, Olive PL. Evaluation of bioreductive drugs in multicell spheroids. Int J Radiat Oncol Biol Phys. 1992;22(4):689-92. PubMed PMID: 1544838.

42: Pan SS, Akman SA, Forrest GL, Hipsher C, Johnson R. The role of NAD(P)H:quinone oxidoreductase in mitomycin C- and porfiromycin-resistant HCT 116 human colon-cancer cells. Cancer Chemother Pharmacol. 1992;31(1):23-31. PubMed PMID: 1458556.

43: Braunschweiger PG, Jones SA, Johnson CS, Furmanski P. Potentiation of mitomycin C and porfiromycin antitumor activity in solid tumor models by recombinant human interleukin 1 alpha. Cancer Res. 1991 Oct 15;51(20):5454-60. PubMed PMID: 1913664.

44: Long BH, Wang L, Lorico A, Wang RC, Brattain MG, Casazza AM. Mechanisms of resistance to etoposide and teniposide in acquired resistant human colon and lung carcinoma cell lines. Cancer Res. 1991 Oct 1;51(19):5275-83. PubMed PMID: 1717144.

45: Tomasz M, Hughes CS, Chowdary D, Keyes SR, Lipman R, Sartorelli AC, Rockwell S. Isolation, identification, and assay of [3H]-porfiromycin adducts of EMT6 mouse mammary tumor cell DNA: effects of hypoxia and dicumarol on adduct patterns. Cancer Commun. 1991 Jul;3(7):213-23. PubMed PMID: 1714285.

46: Braunschweiger PG, Jones SA, Johnson CS, Furmanski P. Interleukin-1 alpha-induced tumour pathophysiologies can be exploited with bioreductive alkylating agents. Int J Radiat Biol. 1991 Jul-Aug;60(1-2):369-72. PubMed PMID: 1677996.

47: Rockwell S, Keyes SR, Loomis R, Kelley M, Vyas DM, Wong H, Doyle TW, Sartorelli AC. Activity of C-7 substituted cyclic acetal derivatives of mitomycin C and porfiromycin against hypoxic and oxygenated EMT6 carcinoma cells in vitro and in vivo. Cancer Commun. 1991 Jun;3(6):191-8. PubMed PMID: 2049227.

48: Keyes SR, Rockwell S, Kennedy KA, Sartorelli AC. Distribution of porfiromycin in EMT6 solid tumors and normal tissues of BALB/c mice. J Natl Cancer Inst. 1991 May 1;83(9):632-7. PubMed PMID: 2023281.

49: Marshall RS, Paterson MC, Rauth AM. Studies on the mechanism of resistance to mitomycin C and porfiromycin in a human cell strain derived from a cancer-prone individual. Biochem Pharmacol. 1991 May 1;41(9):1351-60. PubMed PMID: 1902110.

50: Pattyn G, van Oosterom AT, de Bruijn EA, Tjaden UR. Determination of the new anticancer agent KW 2149, 7-N-[2-[2-(gamma-L-glutamylamino)ethyl)dithio)ethyl]mitomycin C, an analogue of mitomycin C. J Chromatogr. 1991 Mar 8;564(1):352-4. PubMed PMID: 1860933.

51: Kasai M, Kono M, Shirahata K. The derivation of a novel mitomycin skeleton: 3 alpha-alkoxymitomycin. J Antibiot (Tokyo). 1991 Mar;44(3):301-8. PubMed PMID: 2026556.

52: Hughes CS, Irvin CG, Rockwell S. Effect of deficiencies in DNA repair on the toxicity of mitomycin C and porfiromycin to CHO cells under aerobic and hypoxic conditions. Cancer Commun. 1991 Feb;3(2):29-35. PubMed PMID: 1899798.

53: Gustafson DL, Pritsos CA. Inhibition of mitomycin C's aerobic toxicity by the seleno-organic antioxidant PZ-51. Cancer Chemother Pharmacol. 1991;28(3):228-30. PubMed PMID: 1906786.

54: Keyes SR, Loomis R, DiGiovanna MP, Pritsos CA, Rockwell S, Sartorelli AC. Cytotoxicity and DNA crosslinks produced by mitomycin analogs in aerobic and hypoxic EMT6 cells. Cancer Commun. 1991;3(10-11):351-6. PubMed PMID: 1760250.

55: Arora SK, Cox MB, Arjunan P. Structural, conformational, and theoretical binding studies of antitumor antibiotic porfiromycin (N-methylmitomycin C), a covalent binder of DNA, by X-ray, NMR, and molecular mechanics. J Med Chem. 1990 Nov;33(11):3000-8. PubMed PMID: 2231597.

56: Pan SS, Gonzalez H. Mitomycin antibiotic reductive potential and related pharmacological activities. Mol Pharmacol. 1990 Jun;37(6):966-70. PubMed PMID: 2113607.

57: Ohkubo T, Nambara T. Determination of mitomycin C in serum by high-performance liquid chromatography with dual-electrode coulometric detection. J Chromatogr. 1990 May 18;527(2):441-6. PubMed PMID: 2117616.

58: Holden SA, Herman TS, Teicher BA. Addition of a hypoxic cell selective cytotoxic agent (mitomycin C or porfiromycin) to Fluosol-DA/carbogen/radiation. Radiother Oncol. 1990 May;18(1):59-70. PubMed PMID: 2113698.

59: Kono M, Kasai M, Shirahata K, Morimoto M. The derivation of 1a-demethylmitomycin G from mitomycin C. J Antibiot (Tokyo). 1990 Apr;43(4):383-90. PubMed PMID: 2112532.

60: Pan SS. Porfiromycin disposition in oxygen-modulated P388 cells. Cancer Chemother Pharmacol. 1990;27(3):187-93. PubMed PMID: 2265454.

61: Pritsos CA, Keyes SR, Sartorelli AC. Effect of the superoxide dismutase inhibitor, diethyldithiocarbamate, on the cytotoxicity of mitomycin antibiotics. Cancer Biochem Biophys. 1989 Oct;10(4):289-98. PubMed PMID: 2559790.

62: Pan SS, Johnson R, Gonzalez H, Thohan V. Mechanism of transport and intracellular binding of porfiromycin in HCT 116 human colon carcinoma cells. Cancer Res. 1989 Sep 15;49(18):5048-53. PubMed PMID: 2766276.

63: Musser SM, Pan SS, Callery PS. Liquid chromatography-thermospray mass spectrometry of DNA adducts formed with mitomycin C, porfiromycin and thiotepa. J Chromatogr. 1989 Jul 14;474(1):197-207. PubMed PMID: 2504760.

64: Rockwell S, Keyes SR, Sartorelli AC. Modulation of the cytotoxicity of porfiromycin by dicoumarol in vitro and in vivo. Anticancer Res. 1989 Jul-Aug;9(4):817-20. PubMed PMID: 2479329.

65: Keyes SR, Rockwell S, Sartorelli AC. Modification of the metabolism and cytotoxicity of bioreductive alkylating agents by dicoumarol in aerobic and hypoxic murine tumor cells. Cancer Res. 1989 Jun 15;49(12):3310-3. PubMed PMID: 2470504.

66: Marshall RS, Paterson MC, Rauth AM. Deficient activation by a human cell strain leads to mitomycin resistance under aerobic but not hypoxic conditions. Br J Cancer. 1989 Mar;59(3):341-6. PubMed PMID: 2467684; PubMed Central PMCID: PMC2247063.

67: Marshall RS, Rauth AM. Oxygen and exposure kinetics as factors influencing the cytotoxicity of porfiromycin, a mitomycin C analogue, in Chinese hamster ovary cells. Cancer Res. 1988 Oct 15;48(20):5655-9. PubMed PMID: 3167822.

68: Rockwell S, Keyes SR, Sartorelli AC. Preclinical studies of porfiromycin as an adjunct to radiotherapy. Radiat Res. 1988 Oct;116(1):100-13. PubMed PMID: 3186923.

69: Pan SS, Iracki T. Metabolites and DNA adduct formation from flavoenzyme-activated porfiromycin. Mol Pharmacol. 1988 Aug;34(2):223-8. PubMed PMID: 3412325.

70: Sartorelli AC. Therapeutic attack of hypoxic cells of solid tumors: presidential address. Cancer Res. 1988 Feb 15;48(4):775-8. PubMed PMID: 3123053.

71: Keyes SR, Rockwell S, Sartorelli AC. Correlation between drug uptake and selective toxicity of porfiromycin to hypoxic EMT6 cells. Cancer Res. 1987 Nov 1;47(21):5654-7. PubMed PMID: 3664473.

72: Ploegmakers HH, Mertens MJ, van Oort WJ. Improved HPLC-ECD analysis of mitomycin C, porfiromycin, VP 16-213 and VM 26 by implantation of software filters. Anticancer Res. 1987 Nov-Dec;7(6):1315-9. PubMed PMID: 3126702.

73: Fracasso PM, Sartorelli AC. Cytotoxicity and DNA lesions produced by mitomycin C and porfiromycin in hypoxic and aerobic EMT6 and Chinese hamster ovary cells. Cancer Res. 1986 Aug;46(8):3939-44. PubMed PMID: 3089583.

74: Pritsos CA, Sartorelli AC. Generation of reactive oxygen radicals through bioactivation of mitomycin antibiotics. Cancer Res. 1986 Jul;46(7):3528-32. PubMed PMID: 3011250.

75: Claridge CA, Bush JA, Doyle TW, Nettleton DE, Moseley JE, Kimball D, Kammer MF, Veitch J. New mitomycin analogs produced by directed biosynthesis. J Antibiot (Tokyo). 1986 Mar;39(3):437-46. PubMed PMID: 3700245.

76: Beijnen JH, Van der Nat JM, Labadie RP, Underberg WJ. Decomposition of mitomycin and anthracycline cytostatics in cell culture media. Anticancer Res. 1986 Jan-Feb;6(1):39-43. PubMed PMID: 3082277.

77: Sartorelli AC. The role of mitomycin antibiotics in the chemotherapy of solid tumors. Biochem Pharmacol. 1986 Jan 1;35(1):67-9. PubMed PMID: 2416320.

78: Keyes SR, Rockwell S, Sartorelli AC. Porfiromycin as a bioreductive alkylating agent with selective toxicity to hypoxic EMT6 tumor cells in vivo and in vitro. Cancer Res. 1985 Aug;45(8):3642-5. PubMed PMID: 3926306.

79: Iyengar BS, Remers WA. A comparison of mechanisms proposed for the conversion of mitomycins into mitosenes. J Med Chem. 1985 Jul;28(7):963-7. PubMed PMID: 3925148.

80: Mandwal AK, Subramanian PM, Bhatia MC, Kapil RS, Popli SP, Vora VC. Production of mitomycin C and porfiromycin by Streptomyces species. J Nat Prod. 1985 Mar-Apr;48(2):334. PubMed PMID: 3925088.

81: Beijnen JH, den Hartigh J, Underberg WJ. Qualitative aspects of the degradation of mitomycins in alkaline solution. J Pharm Biomed Anal. 1985;3(1):71-9. PubMed PMID: 16867711.

82: Keyes SR, Heimbrook DC, Fracasso PM, Rockwell S, Sligar SG, Sartorelli AC. Chemotherapeutic attack of hypoxic tumor cells by the bioreductive alkylating agent mitomycin C. Adv Enzyme Regul. 1985;23:291-307. PubMed PMID: 3934922.

83: Barbhaiya RH, Papp EA, Van Harken DR, Smyth RD. Pharmacokinetics of mitomycin C in dogs: application of a high-performance liquid chromatographic assay. J Pharm Sci. 1984 Sep;73(9):1220-3. PubMed PMID: 6436466.

84: Fujiwara K, Nakamura H, Kitagawa T, Nakamura N, Saito A, Hara K. Development and application of a sensitive enzyme immunoassay for 7-N-(p-hydroxyphenyl)mitomycin C. Cancer Res. 1984 Sep;44(9):4172-6. PubMed PMID: 6430558.

85: Fujiwara K, Saikusa H, Kitagawa T, Takahashi S, Konishi Y. Specificity of antisera produced against mitomycin C. Cancer Treat Rep. 1983 Dec;67(12):1079-84. PubMed PMID: 6418380.

86: Underberg WJ, Lingeman H. Aspects of the chemical stability of mitomycin and porfiromycin in acidic solution. J Pharm Sci. 1983 May;72(5):549-53. PubMed PMID: 6864504.

87: Underberg WJ, Lingeman H. Determination of pKa values of some prototropic functions in mitomycin and porfiromycin. J Pharm Sci. 1983 May;72(5):553-6. PubMed PMID: 6306206.

88: Iyengar BS, Sami SM, Remers WA, Bradner WT, Schurig JE. Mitomycin C and porfiromycin analogues with substituted ethylamines at position 7. J Med Chem. 1983 Jan;26(1):16-20. PubMed PMID: 6827524.

89: van Hazel GA, Kovach JS. Pharmacokinetics of mitomycin C in rabbit and human. Cancer Chemother Pharmacol. 1982;8(2):189-92. PubMed PMID: 6809356.

90: Iyengar BS, Lin HJ, Cheng L, Remers WA, Bradner WT. Development of new mitomycin C and porfiromycin analogues. J Med Chem. 1981 Aug;24(8):975-81. PubMed PMID: 7328599.

91: Carrano AV, Thompson LH, Stetka DG, Minkler JL, Mazrimas JA, Fong S. DNA crosslinking, sister-chromatid exchange and specific-locus mutations. Mutat Res. 1979 Nov;63(1):175-88. PubMed PMID: 522865.

92: Amer MH, Al-Sarraf M, Vaitkevicius VK. Factors that affect response to chemotherapy and survival of patients with advanced head and neck cancer. Cancer. 1979 Jun;43(6):2202-6. PubMed PMID: 455217.

93: Mayr AC. [Chemotherapy of gastrointestinal tumors (review of the literature)]. Onkologie. 1978 Dec;1(6):248-56. Review. German. PubMed PMID: 83561.

94: Panettiere FJ, Talley RW, Torres J, Lane M. Porfiromycin in the management of epidermoid and transitional cell cancer: a phase II study. Cancer Treat Rep. 1976 Jul;60(7):907-11. PubMed PMID: 795539.

95: Baker LH, Izbicki RM, Vaitkevicius VK. Phase II study of profiromycin vs mitomycin-C utilizing acute intermittent schedules. Med Pediatr Oncol. 1976;2(2):207-13. PubMed PMID: 958162.

96: Rozencweig M, Slavik M, Muggia FM, Carter SK. Overview of early and investigational chemotherapeutic agents in solid tumors. Med Pediatr Oncol. 1976;2(4):417-32. PubMed PMID: 137356.

97: Regelson W. Chemotherapy of gastrointestinal cancer. Int J Radiat Oncol Biol Phys. 1975 Oct-Nov;1(1-2):109-17. PubMed PMID: 61195.

98: Young RC. Chemotherapy of ovarian cancer: past and present. Semin Oncol. 1975 Sep;2(3):267-76. Review. PubMed PMID: 827024.

99: Dowell KE, Armstrong DM, Aust JB, Cruz AB Jr. Systemic chemotherapy of advanced head and neck malignancies. Cancer. 1975 Apr;35(4):1116-20. PubMed PMID: 1116105.

100: Grage TB, Weiss AJ, Wilson W, Reynolds V. Phase I studies of porfiromycin (NSC--56410) in solid tumors. J Surg Oncol. 1975;7(5):415-20. PubMed PMID: 1177472.

101: Schindler D, Davies J. Inhibitors of macromolecular synthesis in yeast. Methods Cell Biol. 1975;12:17-38. Review. PubMed PMID: 53776.

102: Nigro ND, Vaitkevicius VK, Considine B Jr. Combined therapy for cancer of the anal canal: a preliminary report. Dis Colon Rectum. 1974 May-Jun;17(3):354-6. PubMed PMID: 4830803.

103: Razek A, Valeriote F, Vietti T. Survival of hematopoietic and leukemic colony-forming cells in vivo after administration of mitomycin C or porfiromycin. J Natl Cancer Inst. 1973 Dec;51(6):1845-8. PubMed PMID: 4765389.

104: Korsan-Bengtsen K, Bengtsson C, Tibblin E. Blood coagulation, fibrinolysis and platelet function in women aged 38, 46, 50, 54 and 60. The study of women in Gothenburg 1968-1969. Acta Med Scand. 1973 Jun;193(6):543-6. PubMed PMID: 4721963.

105: Selawry OS. Monochemotherapy of bronchogenic carcinoma withs special reference to cell type. Cancer Chemother Rep 3. 1973 Mar;4(2):177-88. Review. PubMed PMID: 4277763.

106: Kojima R, Driscoll J, Mantel N, Goldin A. Some structive-activity relationships for mitomycin C (NSC-26980) derivatives in the treatment of L1210 leukemia. Cancer Chemother Rep 2. 1972 Nov;3(1):121-35. PubMed PMID: 4660731.

107: Izbicki R, al-Sarraf M, Reed ML, Vaughn CB, Vaitkevicius VK. Further clinical trials with porfiromycin (NSC-56410) (large intermittent doses). Cancer Chemother Rep. 1972 Oct;56(5):615-24. PubMed PMID: 4569056.

108: Chirigos MA. Current studies on the therapy of experimental leukemia. Bibl Haematol. 1970;(36):278-92. PubMed PMID: 4950966.

109: Boronow RC, Borromeo RG. Porfiromycin (NSC-56410) for disseminated squamous cancer of the cervix. Cancer Chemother Rep. 1969 Oct;53(5):305-9. PubMed PMID: 5377617.

110: Sidwell RW, Dixon GJ, Compton P, Schabel FM Jr. The effect of treatment with a combination of 6-mercaptopurine and porfiromycin on an established Friend leukemia virus infection. Cancer Res. 1969 Mar;29(3):497-502. PubMed PMID: 5773795.

111: Carter SK. Porfiromycin (NSC-56410)--clinical brochure. Cancer Chemother Rep 3. 1968 Dec;1(1):81-97. PubMed PMID: 4989816.

112: Papac RJ. The effect of porfiromycin on the life cycle of HEP-2 cells in vitro. Tumori. 1967 Nov-Dec;53(6):517-21. PubMed PMID: 5591988.

113: Foley HT, Shnider BI, Gold GL, Matias PI, Colsky J, Miller SP. Phase 1 studies of porfiromycin (NSC-56410). Cancer Chemother Rep. 1967 Sep;51(5):283-93. PubMed PMID: 4864580.

114: WHITE JR, WHITE HL. PHENETHYL ALCOHOL SYNERGISM WITH MITOMYCIN C, PORFIROMYCIN, AND STREPTONIGRIN. Science. 1964 Sep 18;145:1312-3. PubMed PMID: 14173417.

115: GARRETT ER, SCHROEDER W. PREDICTION OF STABILITY IN PAHRMACEUTICAL PREPARATIONS. 13. STABILITY, SPECTROPHOTOMETRIC , AND BIOLOGICAL ASSAY OF THE ANTIBIOTIC PORFIROMYCIN IN PHARMACEUTICALLY USEFUL PH RANGES. J Pharm Sci. 1964 Aug;53:917-23. PubMed PMID: 14241805.

116: IYER VN, SZYBALSKI W. MITOMYCINS AND PORFIROMYCIN: CHEMICAL MECHANISM OF ACTIVATION AND CROSS-LINKING OF DNA. Science. 1964 Jul 3;145:55-8. PubMed PMID: 14162693.

117: EVANS JS, BOSTWICK L, MENGEL GD. SYNERGISM OF THE ANTINEOPLASTIC ACTIVITY OF CYTOSINE ARABINOSIDE BY PORFIROMYCIN. Biochem Pharmacol. 1964 Jul;13:983-8. PubMed PMID: 14201140.

118: GARRETT ER. THE PHYSICAL CHEMICAL CHARACTERIZATION OF THE PRODUCTS, EQUILIBRIA, AND KINETICS OF THE COMPLEX TRANSFORMATIONS OF THE ANTIBIOTIC PORFIROMYCIN. J Med Chem. 1963 Sep;6:488-501. PubMed PMID: 14173567.

119: DUVALL LR. PORFIROMYCIN. Cancer Chemother Rep. 1963 Jul;30:35-43. PubMed PMID: 14051502.

120: WAKAKI S, HARADA Y, UZU K, WHITFIELD GB, WILSON AN, KALOWSKY A, STAPLEY EO, WOLF FJ, WILLIAMS DE. The identity of porfiromycin and methyl mitomycin. Antibiot Chemother. 1962 Jul;12:469-71. PubMed PMID: 14004453.

121: PITTILLO RF, QUINNELLY BG. Studies on the antimicrobial action of porfiromycin. Antibiot Chemother. 1962 Jan;12:55-64. PubMed PMID: 14486994.

122: EVANS JS, MUSSER EA, GRAY JE. Porfiromycin antitumor and toxicopathologic studies. Antibiot Chemother. 1961 Jul;11:445-53. PubMed PMID: 13697588.